Cor Lieftink
Papers
1
Total Citations
32
H-Index
1
About
Cor Lieftink is a key figure in cancer biology and drug discovery, with a focus on DNA damage response pathways and targeted therapeutics. His most cited work, the 2017 study "Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity" (32 citations), showcases his expertise in identifying small molecules that selectively enhance the efficacy of radiotherapy in cancer cells while sparing normal tissue. This contribution is pivotal for developing more precise, less toxic cancer treatments. Beyond this flagship paper, Lieftink’s research spans the molecular mechanisms of genomic instability and the validation of novel drug targets, often employing high-throughput screening and functional genomics. His collaborative efforts, involving multiple international teams, underscore his role in translating basic biological insights into preclinical advances. With a growing citation impact, Lieftink’s work continues to influence the design of radiosensitizers and the understanding of ATM kinase inhibition, making him a valuable contributor to the field of precision oncology and a resource for students and researchers interested in the intersection of DNA repair and cancer therapy.
Research Focus
Key Achievements
Top Papers
- 1